Shares of Insys Therapeutics Inc. (NASDAQ:INSY) saw unusually-strong trading volume on Wednesday . Approximately 797,596 shares were traded during trading, an increase of 34% from the previous session’s volume of 596,690 shares.The stock last traded at $18.79 and had previously closed at $19.38.

Several analysts recently issued reports on INSY shares. Jefferies Group cut their target price on shares of Insys Therapeutics from $23.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, April 12th. Piper Jaffray Cos. restated an “overweight” rating and set a $28.00 target price on shares of Insys Therapeutics in a research report on Wednesday, July 6th. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, June 13th. Janney Montgomery Scott started coverage on shares of Insys Therapeutics in a research report on Thursday, April 14th. They set a “buy” rating and a $22.00 target price for the company. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $32.00 target price (down from $44.00) on shares of Insys Therapeutics in a research report on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $24.67.

The firm’s 50-day moving average is $15.16 and its 200 day moving average is $15.76. The stock has a market cap of $1.34 billion and a price-to-earnings ratio of 28.27.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings data on Wednesday, August 3rd. The specialty pharmaceutical company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by $0.01. The firm earned $67.10 million during the quarter, compared to analyst estimates of $66.90 million. During the same quarter in the previous year, the firm earned $0.21 EPS. The business’s revenue for the quarter was down 13.6% compared to the same quarter last year. On average, analysts forecast that Insys Therapeutics Inc. will post $0.40 EPS for the current fiscal year.

In other news, VP Daniel Brennan sold 5,781 shares of Insys Therapeutics stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $19.16, for a total value of $110,763.96. Following the transaction, the vice president now directly owns 1 shares in the company, valued at $19.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Theodore H. Stanley sold 16,000 shares of the business’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $16.27, for a total value of $260,320.00. Following the transaction, the director now owns 18,000 shares in the company, valued at $292,860. The disclosure for this sale can be found here.

Other institutional investors have recently modified their holdings of the company. Globeflex Capital L P raised its position in shares of Insys Therapeutics by 99,000.0% in the fourth quarter. Globeflex Capital L P now owns 39,640 shares of the specialty pharmaceutical company’s stock valued at $1,135,000 after buying an additional 39,600 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Insys Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,625 shares of the specialty pharmaceutical company’s stock valued at $1,249,000 after buying an additional 754 shares in the last quarter. Airain ltd purchased a new position in shares of Insys Therapeutics during the fourth quarter valued at about $1,309,000. Bank of Montreal Can raised its position in shares of Insys Therapeutics by 9.4% in the fourth quarter. Bank of Montreal Can now owns 66,646 shares of the specialty pharmaceutical company’s stock valued at $1,909,000 after buying an additional 5,733 shares in the last quarter. Finally, California Public Employees Retirement System raised its position in shares of Insys Therapeutics by 178.7% in the fourth quarter. California Public Employees Retirement System now owns 97,000 shares of the specialty pharmaceutical company’s stock valued at $2,777,000 after buying an additional 62,200 shares in the last quarter.

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.